MNKDMannKind Corporation

MannKind's (MNKD) increasingly diversified portfolio is seen bringing in higher revenue in H2, with

UTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that reshape future growth.

MannKind Corp (MNKD) reports 43% revenue surge to $109.4 million, fueled by Furosix momentum and Afrezza pediatric launch, despite a GAAP net loss.

MannKind (NASDAQ:MNKD) reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased spending tied to product launches and development programs. The company recorded a GAAP net loss of $19

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

MannKind (MNKD) delivered earnings and revenue surprises of -200.00% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

MannKind (NASDAQ:MNKD) reported Phase 1b results for its inhaled nintedanib dry-powder inhalation, or DPI, candidate in patients with idiopathic pulmonary fibrosis, or IPF, saying the seven-day study met its objective of demonstrating short-term safety and tolerability. The company’s INFLO-1 trial

Mannkind Corporation shares are trading higher as the company recently announced the U.S. Food and Drug Administration’s (FDA) approval of Furoscix ReadyFlow, an at-home treatment option for adults with heart failure or chronic kidney disease. MannKind (MNKD) Jumps On FDA...

MannKind (MNKD) is in focus after the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an at-home autoinjector for fluid overload in heart failure or chronic kidney disease, alongside a roughly $50 million private placement. See our latest analysis for MannKind. The FDA approval of Furoscix ReadyFlow and the roughly $50 million private placement come after a mixed period for MannKind, with a 90 day share price return of 52.96% but a year to date share price decline of 26.25%,...

MannKind stock has declined 26.2% year to date, yet valuation checks suggest it may now be trading below an estimated intrinsic value based on a Discounted Cash Flow (DCF) approach and market multiples. The year to date fall of 26.2% raises the question of whether recent weakness has pushed MannKind into undervalued territory. FDA approval of Furoscix ReadyFlow can support expectations for future cash flows, while the recent US$50,000,000 private placement highlights ongoing funding needs...

MannKind Corporation has now received U.S. FDA approval for Furoscix ReadyFlow, an at-home autoinjector delivering an IV‑equivalent 80 mg/mL furosemide dose in under 10 seconds to treat edema in adults with heart failure or chronic kidney disease. This second Furoscix presentation could materially extend MannKind’s reach beyond hospitals into outpatient and home-based fluid management, broadening its cardiology and nephrology footprint. We’ll now examine how launching an at-home...

FDA approved MannKind’s Furoscix ReadyFlow on Friday.

MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an auto-injector designed to deliver an 80-milligram dose of subcutaneous furosemide in five to 10 seconds for the management of fluid overload. Chief Executive Officer Michael Castagna said the approval

MannKind (MNKD) is expected to get FDA approval for the Furoscix ReadyFlow auto injector by July 26

MannKind Corporation (NASDAQ:MNKD) shares climbed around 6% on Friday after the biotechnology company announced U. S.

The FDA is expected to announce its decision on MannKind’s sNDA on July 26, 2026.

Performance-based RSUs vested at 83% of target, reflecting MannKind's stock performance against industry benchmarks. Singh retains ~479,000 shares valued at $1.96 million.

Binder's disposition followed vesting of performance-based awards tied to the company's total shareholder return relative to the Russell 3000 Pharmaceutical & Biotechnology Index.

This disposition was tied to vesting of performance-based RSUs at 83% of the target.

Tross disposed of 65,808 shares to cover tax withholding from a vested performance award, retaining over 1 million shares in the company.

Castagna retains 2.4 million shares after the non-discretionary sale tied to RSU vesting, maintaining substantial alignment with the biopharmaceutical company.